Avingtrans’ Energy Steel awarded a $4.1M contract from Nuclear Waste Partnership

Avingtrans plc

Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced Energy Steel has been awarded a $4.1M contract from Nuclear Waste Partnership LLC.

Drew Baker, President of Energy Steel, commented:

“We’re delighted that Energy Steel continues to gather momentum and this contract supports continuing growth. Energy Steel has been serving the nuclear industry over the last 40 years, and we are honored to support one of the most ambitious energy projects in the world today.”

Energy Steel, part of the Engineered Pumps and Motors Division of Avingtrans plc and leader in high quality components, fabrications, and materials for the nuclear energy sector, has been awarded a $4.1M contract from Nuclear Waste Partnership LLC. The contract, which is expected to be completed by June 2023, includes the supply of materials and subassemblies required for the waste isolation pilot plant (WIPP), the nation’s only deep geological long-lived radioactive waste repository. The materials and subassemblies will be used in the construction of the TRUPACT-II and HalfPACT Type B packages developed by the U.S. Department of Energy. Both packages are utilized as a safe means for the transportation of transuranic materials and designed to reduce the number of radioactive shipments.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Avingtrans Plc Building Momentum in Nuclear and Medical Imaging as Margins Surge (Video)

Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out.

Avingtrans reports higher interim profit and strong FY26 visibility

Avingtrans PLC reported flat first-half revenue of £78.1m for the six months to 30 November 2025, with adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax rising 27.1% to £5.7m.

Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

Avingtrans plc has announced that Stuart Gall officially assumed the role of Chief Executive Officer of its medical and industrial imaging division on 1 January 2026.

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.

    Search

    Search